Report from the Catalan Agency for Health Technology Assessment (CAHTA). Efficacy and safety of thrombolytic therapy in pulmonary thromboembolism.
D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D011655:Pulmonary Embolism / Q000188:drug therapy*; D012449:Safety; D013030:Spain; D013673:Technology Assessment, Biomedical; D015912:Thrombolytic Therapy / Q000009:adverse effects
D005343:Fibrinolytic Agents